EMR Resource For: Epic®

NCODA
NCODA.ORG

Ovarian Cancer: Effective Practices to Benefit Patients
- In advanced ovarian cancer, genetic testing rates hover around 50%.[1]
- Only 49% of patients received maintenance therapy in second line or greater therapy.[2]
- Current rates warrant improved methods and practices to enable professionals to both identify and offer PARP-Inhibitors to appropriate patients at the right time.
  - **NCODA's Positive Quality Intervention (PQI)** on this topic provides practical guidance and is available here: www.ncoda.org/ovarian-cancer-parp-inhibitor-eligibility

---

This EMR Resource provides simple step-by-step instructions to:

1. Run a Report: to search for all ovarian cancer patients

2. Review Chart: to conduct a clinical assessment

3. Create Reminders and Track: key treatment milestones and timing of therapy

---

1. Run a Report

To identify all ovarian cancer patients within the EMR, search by "Ovarian"

Work with the
Epic Support Team
directly to run the report

Alternatively, work with your
**Information Technology (IT) Department** to run the report

2. Review Chart

From the patient list, select a patient and review each patient case to determine

Genetics / mutational status (BRCA and other HRD)

| 1 | Select **Chart Review** from vertical toolbar | 2 | Select **Pathology** tab | 3 | If not complete, discuss with provider |

Current treatment and disease stage (primary, in response, recurrence)

Assess within recent **Progress Note** or **Visit Note**

Eligibility for PARP-I

Discuss with provider and begin prescription creation

3. Create Reminders and Track

For each patient, create a tracking system and reminder flag via treatment plan or protocol

Work with the **Epic Support Team** to:

| 1 | Incorporate key reminders into the **Treatment Plan** | 2 | More effectively, implement into the **Protocol** itself |

Create reminders for evaluation of genetics and treatment options:

| 1 | At the end of Cycle 5 of initial chemotherapy (if not done) | 2 | Within 3 months of the end of initial chemotherapy (if in response) | 3 | If recurrent disease not in treatment, schedule provider evaluation |

1. Randall LM, Aydin E, Louie-Gao M, Hazard S, Westin SN. A retrospective analysis of real-world tumor BRCA (tBRCA) testing trends in ovarian cancer before and after PARP inhibitor approvals. Presented at the 17th Biennial Meeting of the International Gynecologic Cancer Society; Kyoto, Japan: 2018.
2. Garofalo D, Verma-Kurvari S, Aydin E, et al. Real world data analysis of ovarian cancer maintenance utilization among maintenance eligible patients. Presented at the American Society of Clinical Oncology Annual Congress; Chicago, IL: 2019.

NCODA

NCODA.ORG